Tackling Mantle Cell Lymphoma in Europe
(2022) In Healthcare (Switzerland) 10(9).- Abstract
An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted advances in outcomes over the last decade, but highlighted issues constituting barriers to better care. The list notably included availability of newer treatments, infrastructure and funding for related testing, and shortages of relevant skills and of research support. The prospect of improvements was held to reside in closer coordination and cooperation within and between individual countries, and in changes in policy and scale of investment at both national and EU levels.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/da2339b9-510d-4024-bfd6-2375ccb1de3d
- author
- Horgan, Denis ; Walewski, Jan ; Aurer, Igor ; Visco, Carlo ; Giné, Eva ; Fetica, Bogdan ; Jerkeman, Mats LU ; Kozaric, Marta ; da Silva, Maria Gomes and Dreyling, Martin
- organization
- publishing date
- 2022-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- barriers, care, EU level, healthcare, infrastructure, mantle cell lymphoma, MCL, personalized medicine, policy framework, treatment
- in
- Healthcare (Switzerland)
- volume
- 10
- issue
- 9
- article number
- 1682
- publisher
- MDPI AG
- external identifiers
-
- scopus:85138525990
- pmid:36141294
- ISSN
- 2227-9032
- DOI
- 10.3390/healthcare10091682
- language
- English
- LU publication?
- yes
- id
- da2339b9-510d-4024-bfd6-2375ccb1de3d
- date added to LUP
- 2022-12-14 10:05:41
- date last changed
- 2024-09-16 01:12:50
@article{da2339b9-510d-4024-bfd6-2375ccb1de3d, abstract = {{<p>An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted advances in outcomes over the last decade, but highlighted issues constituting barriers to better care. The list notably included availability of newer treatments, infrastructure and funding for related testing, and shortages of relevant skills and of research support. The prospect of improvements was held to reside in closer coordination and cooperation within and between individual countries, and in changes in policy and scale of investment at both national and EU levels.</p>}}, author = {{Horgan, Denis and Walewski, Jan and Aurer, Igor and Visco, Carlo and Giné, Eva and Fetica, Bogdan and Jerkeman, Mats and Kozaric, Marta and da Silva, Maria Gomes and Dreyling, Martin}}, issn = {{2227-9032}}, keywords = {{barriers; care; EU level; healthcare; infrastructure; mantle cell lymphoma; MCL; personalized medicine; policy framework; treatment}}, language = {{eng}}, number = {{9}}, publisher = {{MDPI AG}}, series = {{Healthcare (Switzerland)}}, title = {{Tackling Mantle Cell Lymphoma in Europe}}, url = {{http://dx.doi.org/10.3390/healthcare10091682}}, doi = {{10.3390/healthcare10091682}}, volume = {{10}}, year = {{2022}}, }